<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03249493</url>
  </required_header>
  <id_info>
    <org_study_id>2016-001</org_study_id>
    <nct_id>NCT03249493</nct_id>
  </id_info>
  <brief_title>Monitoring Of Viral Load In Decentralised Area in Vietnam</brief_title>
  <acronym>MOVIDA-2</acronym>
  <official_title>Monitoring Of Viral Load In Decentralised Area in Vietnam : Improving Access to Viral Load Monitoring in HIV-infected Patients on ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanoi University of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As of today, HIV-infected patients followed in decentralized area have little or even no&#xD;
      access to viral load monitoring because laboratories able to perform this biological&#xD;
      measurement are only in large cities, and because plasma transfer to these laboratories is&#xD;
      complex and very costly.&#xD;
&#xD;
      Blood sampling using dried blood spots (DBS) could overcome these difficulties. The goal of&#xD;
      this operational research is to document the feasibility of DBS use in decentralised area to&#xD;
      monitor viral load, to evaluate the virological response on ART, and to compare the&#xD;
      virological response between injecting drug users (IDU) and the other patients, as IDU&#xD;
      represent a large proportion of HIV-infected patients who may have a lower access/adherence&#xD;
      to care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MOVIDA project is a longitudinal observational study enrolling patients who initiate ART&#xD;
      in decentralized areas requiring individual data and blood samples collected in routine HIV&#xD;
      care.&#xD;
&#xD;
      This project aims at evaluating and providing operability data of the use of Dried Blood&#xD;
      Spots (DBS) as sampling tool to measure and monitor the HIV viral load in real life in rural&#xD;
      decentralized areas in Vietnam.&#xD;
&#xD;
      This operational project would contribute to:&#xD;
&#xD;
        -  the provision of viral load measurements in patients from rural decentralized areas,&#xD;
&#xD;
        -  the improvement of the proportion of patients in virological success on ART, and hence&#xD;
           to reduce the proportion of patients with acquired HIV drug resistance,&#xD;
&#xD;
        -  the improvement of general HIV care and to establish an observatory of HIV drug&#xD;
           resistance,&#xD;
&#xD;
        -  strengthen national capacities through capitalization and exchange of good practices of&#xD;
           blood sampling using DBS system to expand to other indications than HIV VL measurement.&#xD;
&#xD;
      To achieve this goal, clinical and laboratory staff will be trained to the management of the&#xD;
      MOVIDA project (enrollment of patients; sample collection, management and analysis; data&#xD;
      collection) before the operational observational study. Patients on the antiretroviral (ART)&#xD;
      initiation visit will be informed about the study and invited to participate, before&#xD;
      collection of blood to prepare DBS and collection of clinical data already routinely&#xD;
      collected in the patient medical records. The blood collection (5ml) will be repeated at 6,&#xD;
      12 and 24 months during follow-up visits already planned according to the current national&#xD;
      guidelines for the ART delivery.&#xD;
&#xD;
      The samples collected (5ml of blood) will be analyzed in a local central laboratory using the&#xD;
      m2000rt Abbott techniques. Analysis results (VL and when necessary HIV Drug Resistance&#xD;
      genotyping) will be available to the medical doctor in order to adapt the patient treatment&#xD;
      appropriately. A set of randomly selected DBS will be shipped to France for centralized&#xD;
      quality control analyses.&#xD;
&#xD;
      A socio-anthropological qualitative study will also be implemented targeting patients,&#xD;
      health-care staff and peer health workers to apprehend their understanding of VL, and to&#xD;
      better define determinants of adherence and attendance to clinical visits. This will help&#xD;
      local health authorities adapt the messages and the initiatives to improve adherence to ART&#xD;
      and attendance to care follow-up.&#xD;
&#xD;
      The study duration is 36 months with a 6 months period of enrollment and will be conducted in&#xD;
      6 provinces where 1000 patients are to be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virological success at 24 months of ART</measure>
    <time_frame>24 months (+/- 1 month) after ART initiation</time_frame>
    <description>Patients with a VL &lt;1000 copies/mL at 24 months of ART</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcomes related to DBS transfer</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Delay (days) between DBS collection and transfer to central laboratory&#xD;
Delay (days) between DBS collection and reception at central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes related to quality of DBS samples</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>- Aspect of DBS at reception at central laboratory (qualitative evaluation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes related to delay concerning the return of viral load result</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Delay (days) between reception at central laboratory and viral load quantification&#xD;
Delay (days) between DBS collection and reception of the result at the care site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes related to ability of DBS to provide viral load result</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>- Proportion of DBS not allowing viral load quantification (number of DBS not allowing VL quantification/total number of DBS samples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes related to ability of DBS to provide HIV drug resistance result</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>- Proportion of DBS not allowing HIV drug resistance (number of DBS not allowing HIV drug resistance /total number of DBS samples with VL confirmed&gt;1000cp/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of viral load result on second-line ART initiation</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>- Number of patients who initiate second-line ART during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of viral load result on second-line ART initiation in term of delay</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>- Delay (days) between reception of the viral load results at the care site and second-line ART initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virological success at 6 and at 12 months of ART</measure>
    <time_frame>At 6 and 12 months of ART</time_frame>
    <description>Patients with a VL &lt;1000 copies/mL at 6 and at 12 months of ART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure at 6, 12 and 24 months of ART</measure>
    <time_frame>At 6, 12 and 24 months of ART</time_frame>
    <description>- Proportion of patients with 2 consecutive viral load &gt;= 1000 copies/mL (the second viral load being measured within 2 to 3 months from the first one after strengthening of adherence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART</measure>
    <time_frame>At 6, 12 and 24 months of ART</time_frame>
    <description>- Proportion of patients in virological failure and for whom the virus is harbouring HIV drug resistances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART</measure>
    <time_frame>At 6, 12 and 24 months of ART</time_frame>
    <description>- Profiles of HIV durg resistance in patients in virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline HIV drug resistance in case of virological failure</measure>
    <time_frame>ART initiation</time_frame>
    <description>- Proportion of patients identified in virological failure during the follow-up on ART, and for whom the virus presented HIV drug resistance at ART initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline HIV drug resistance</measure>
    <time_frame>ART initiation</time_frame>
    <description>- proportion of patients for whom the virus presented HIV drug resistance at ART initiation, in a random selection of patients enrolled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Patients who died while on ART during the follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attrition</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>patients who are lost to follow-up (not seen for &gt;3 months) after they initiated ART</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">584</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Dried Blood Spot</condition>
  <condition>Viral Load</condition>
  <arm_group>
    <arm_group_label>HIV Injection drug users</arm_group_label>
    <description>Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV Non injection drug users</arm_group_label>
    <description>Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample on DBS</intervention_name>
    <description>We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.&#xD;
HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results &gt; 1000 cp/mL</description>
    <arm_group_label>HIV Injection drug users</arm_group_label>
    <arm_group_label>HIV Non injection drug users</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples on Dried Blood spot cards&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The key population for this research project is HIV-positive patients who initiate ART&#xD;
        followed in 24 out-patient clinics (OPCs) located in decentralised areas in two provinces,&#xD;
        where laboratories facilities are not easily accessible and where VL monitoring is&#xD;
        extremely scarce.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed HIV-1 infection,&#xD;
&#xD;
          -  age at enrolment ≥18 years,&#xD;
&#xD;
          -  ART naïve (women exposed through PMTCT are eligible),&#xD;
&#xD;
          -  consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  negative for HIV,&#xD;
&#xD;
          -  age at enrolment &lt;18 years,&#xD;
&#xD;
          -  ART experienced (excepted PMTCT),&#xD;
&#xD;
          -  not consenting to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fabien TAIEB, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoann Madec, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yen Bai medical center</name>
      <address>
        <city>Yen Bai</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Taieb F, Tran Hong T, Ho HT, Nguyen Thanh B, Pham Phuong T, Viet Ta D, Le Thi Hong N, Ba Pham H, Nguyen LTH, Nguyen HT, Nguyen TT, Tuaillon E, Delaporte E, Le Thi H, Tran Thi Bich H, Nguyen TA, Madec Y. First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS One. 2018 Feb 9;13(2):e0191920. doi: 10.1371/journal.pone.0191920. eCollection 2018.</citation>
    <PMID>29425216</PMID>
  </reference>
  <reference>
    <citation>Taieb F, Tram TH, Ho HT, Pham VA, Nguyen L, Pham BH, Tong LA, Tuaillon E, Delaporte E, Nguyen AT, Bui DD, Do N, Madec Y. Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infect Dis. 2016 Jul 7;3(3):ofw142. doi: 10.1093/ofid/ofw142. eCollection 2016 Sep.</citation>
    <PMID>27704001</PMID>
  </reference>
  <results_reference>
    <citation>Nguyen TA, Tran TH, Nguyen BT, Pham TTP, Hong Le NT, Ta DV, Phan HTT, Nguyen LH, Ait-Ahmed M, Ho HT, Taieb F, Madec Y; MOVIDA 2 study group. Feasibility of dried blood spots for HIV viral load monitoring in decentralized area in North Vietnam in a test-and-treat era, the MOVIDA project. PLoS One. 2020 Apr 9;15(4):e0230968. doi: 10.1371/journal.pone.0230968. eCollection 2020.</citation>
    <PMID>32271796</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>May 16, 2022</last_update_submitted>
  <last_update_submitted_qc>May 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Decentralised Area</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Non applicable</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03249493
org study id: 2016-001
nct id: NCT03249493
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
As of today, HIV-infected patients followed in decentralized area have little or even no
      access to viral load monitoring because laboratories able to perform this biological
      measurement are only in large cities, and because plasma transfer to these laboratories is
      complex and very costly.

      Blood sampling using dried blood spots (DBS) could overcome these difficulties. The goal of
      this operational research is to document the feasibility of DBS use in decentralised area to
      monitor viral load, to evaluate the virological response on ART, and to compare the
      virological response between injecting drug users (IDU) and the other patients, as IDU
      represent a large proportion of HIV-infected patients who may have a lower access/adherence
      to care.
The MOVIDA project is a longitudinal observational study enrolling patients who initiate ART
      in decentralized areas requiring individual data and blood samples collected in routine HIV
      care.

      This project aims at evaluating and providing operability data of the use of Dried Blood
      Spots (DBS) as sampling tool to measure and monitor the HIV viral load in real life in rural
      decentralized areas in Vietnam.

      This operational project would contribute to:

        -  the provision of viral load measurements in patients from rural decentralized areas,

        -  the improvement of the proportion of patients in virological success on ART, and hence
           to reduce the proportion of patients with acquired HIV drug resistance,

        -  the improvement of general HIV care and to establish an observatory of HIV drug
           resistance,

        -  strengthen national capacities through capitalization and exchange of good practices of
           blood sampling using DBS system to expand to other indications than HIV VL measurement.

      To achieve this goal, clinical and laboratory staff will be trained to the management of the
      MOVIDA project (enrollment of patients; sample collection, management and analysis; data
      collection) before the operational observational study. Patients on the antiretroviral (ART)
      initiation visit will be informed about the study and invited to participate, before
      collection of blood to prepare DBS and collection of clinical data already routinely
      collected in the patient medical records. The blood collection (5ml) will be repeated at 6,
      12 and 24 months during follow-up visits already planned according to the current national
      guidelines for the ART delivery.

      The samples collected (5ml of blood) will be analyzed in a local central laboratory using the
      m2000rt Abbott techniques. Analysis results (VL and when necessary HIV Drug Resistance
      genotyping) will be available to the medical doctor in order to adapt the patient treatment
      appropriately. A set of randomly selected DBS will be shipped to France for centralized
      quality control analyses.

      A socio-anthropological qualitative study will also be implemented targeting patients,
      health-care staff and peer health workers to apprehend their understanding of VL, and to
      better define determinants of adherence and attendance to clinical visits. This will help
      local health authorities adapt the messages and the initiatives to improve adherence to ART
      and attendance to care follow-up.

      The study duration is 36 months with a 6 months period of enrollment and will be conducted in
      6 provinces where 1000 patients are to be enrolled.
observational model: Cohort
time perspective: Prospective
measure: Virological success at 24 months of ART
time frame: 24 months (+/- 1 month) after ART initiation
description: Patients with a VL <1000 copies/mL at 24 months of ART
measure: Outcomes related to DBS transfer
time frame: through study completion, an average of 2 years
description: Delay (days) between DBS collection and transfer to central laboratory
Delay (days) between DBS collection and reception at central laboratory
measure: Outcomes related to quality of DBS samples
time frame: through study completion, an average of 2 years
description: - Aspect of DBS at reception at central laboratory (qualitative evaluation)
measure: Outcomes related to delay concerning the return of viral load result
time frame: through study completion, an average of 2 years
description: Delay (days) between reception at central laboratory and viral load quantification
Delay (days) between DBS collection and reception of the result at the care site
measure: Outcomes related to ability of DBS to provide viral load result
time frame: through study completion, an average of 2 years
description: - Proportion of DBS not allowing viral load quantification (number of DBS not allowing VL quantification/total number of DBS samples)
measure: Outcomes related to ability of DBS to provide HIV drug resistance result
time frame: through study completion, an average of 2 years
description: - Proportion of DBS not allowing HIV drug resistance (number of DBS not allowing HIV drug resistance /total number of DBS samples with VL confirmed>1000cp/mL)
measure: Impact of viral load result on second-line ART initiation
time frame: through study completion, an average of 2 years
description: - Number of patients who initiate second-line ART during the study
measure: Impact of viral load result on second-line ART initiation in term of delay
time frame: through study completion, an average of 2 years
description: - Delay (days) between reception of the viral load results at the care site and second-line ART initiation
measure: virological success at 6 and at 12 months of ART
time frame: At 6 and 12 months of ART
description: Patients with a VL <1000 copies/mL at 6 and at 12 months of ART
measure: Virological failure at 6, 12 and 24 months of ART
time frame: At 6, 12 and 24 months of ART
description: - Proportion of patients with 2 consecutive viral load >= 1000 copies/mL (the second viral load being measured within 2 to 3 months from the first one after strengthening of adherence)
measure: HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART
time frame: At 6, 12 and 24 months of ART
description: - Proportion of patients in virological failure and for whom the virus is harbouring HIV drug resistances
measure: Description of HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART
time frame: At 6, 12 and 24 months of ART
description: - Profiles of HIV durg resistance in patients in virological failure
measure: Baseline HIV drug resistance in case of virological failure
time frame: ART initiation
description: - Proportion of patients identified in virological failure during the follow-up on ART, and for whom the virus presented HIV drug resistance at ART initiation
measure: Baseline HIV drug resistance
time frame: ART initiation
description: - proportion of patients for whom the virus presented HIV drug resistance at ART initiation, in a random selection of patients enrolled
measure: Mortality
time frame: through study completion, an average of 2 years
description: Patients who died while on ART during the follow-up
measure: Attrition
time frame: through study completion, an average of 2 years
description: patients who are lost to follow-up (not seen for >3 months) after they initiated ART
arm group label: HIV Injection drug users
description: Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
arm group label: HIV Non injection drug users
description: Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
intervention type: Other
intervention name: Blood sample on DBS
description: We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.
HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL
arm group label: HIV Injection drug users
arm group label: HIV Non injection drug users
Whole blood samples on Dried Blood spot cards
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
last name: Fabien TAIEB, MD
role: Principal Investigator
affiliation: Institut Pasteur
last name: Yoann Madec, PhD
role: Principal Investigator
affiliation: Institut Pasteur
facility: 
country: Vietnam
citation: Taieb F, Tran Hong T, Ho HT, Nguyen Thanh B, Pham Phuong T, Viet Ta D, Le Thi Hong N, Ba Pham H, Nguyen LTH, Nguyen HT, Nguyen TT, Tuaillon E, Delaporte E, Le Thi H, Tran Thi Bich H, Nguyen TA, Madec Y. First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS One. 2018 Feb 9;13(2):e0191920. doi: 10.1371/journal.pone.0191920. eCollection 2018.
PMID: 29425216
citation: Taieb F, Tram TH, Ho HT, Pham VA, Nguyen L, Pham BH, Tong LA, Tuaillon E, Delaporte E, Nguyen AT, Bui DD, Do N, Madec Y. Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infect Dis. 2016 Jul 7;3(3):ofw142. doi: 10.1093/ofid/ofw142. eCollection 2016 Sep.
PMID: 27704001
citation: Nguyen TA, Tran TH, Nguyen BT, Pham TTP, Hong Le NT, Ta DV, Phan HTT, Nguyen LH, Ait-Ahmed M, Ho HT, Taieb F, Madec Y; MOVIDA 2 study group. Feasibility of dried blood spots for HIV viral load monitoring in decentralized area in North Vietnam in a test-and-treat era, the MOVIDA project. PLoS One. 2020 Apr 9;15(4):e0230968. doi: 10.1371/journal.pone.0230968. eCollection 2020.
PMID: 32271796
responsible party type: Sponsor
mesh term: Acquired Immunodeficiency Syndrome
mesh term: HIV Infections
sharing ipd: No
ipd description: Non applicable